60 Percent of Eligible Early Breast Cancer Patients Not Receiving CDK4/6 Inhibitors Due to Access and Management Barriers

A recent analysis presented at the Miami Breast Cancer Conference revealed that 60% of eligible early breast cancer patients are not receiving CDK4/6 inhibitors, a class of drugs used in treatment. Experts discussing the findings highlighted disparities in usage between academic and community healthcare settings, with older patients and those with fewer lymph nodes being particularly affected. The panel also identified several unmet needs related to the use of these inhibitors, including challenges in managing side effects, reducing monitoring burdens, and addressing financial and administrative obstacles.

The discussion pointed to quality-of-life concerns as a significant issue for patients undergoing treatment with CDK4/6 inhibitors. Adverse effects such as fatigue and diarrhea were noted as areas requiring improved management strategies. Additionally, frequent laboratory monitoring associated with these treatments was cited as a burden for both patients and healthcare providers. Financial toxicity and administrative hurdles further complicate access to these therapies, impacting both patient care and the workload of medical staff. Panelists emphasized that these barriers contribute to underutilization despite the eligibility of many patients for this treatment option.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: October 9, 2025

Author

Mark Chiang